Background Hyperactivity of the alternative complement pathway is the principle defect in
C3 glomerulopathies (C3G). Eculizumab, a monoclonal antibody that binds C5 to prevent …

Abstract Background C3 glomerulopathy (C3G) is a rare, but severe glomerular disease with
grim prognosis. The complex pathogenesis is just unfolding, and involves acquired as well …

Abstract C3 glomerulopathy (C3G) is characterized by C3 deposits with minimal
immunoglobulin deposition caused by alternative complement pathway dysregulation …

Background Eculizumab may be used to treat C3-glomerulopathy (C3G), a rare but severe
glomerular disease. Diagnosis and Treatment Patients 1, 2 and 3 were diagnosed with …

Eculizumab might benefit C3 glomerulopathies mediated by dysregulation of the alternative
complement pathway. Here, we report renal biopsy findings before and after eculizumab …

C3 glomerulopathy (C3G) is a prototypic complement-mediated kidney disease. Rapidly
progressive forms of C3G usually respond poorly to conventional treatments. We report on …

Background Cases reports and small series of patients with C3 glomerulopathy have
reported variable efficacy of eculizumab. Study Design Case series of C3 glomerulopathy …

Eculizumab is an anti-C5 antibody that inhibits C5 cleavage and prevents the generation of
the terminal complement complex C5b-9. Eculizumab is licensed to treat paroxysmal …

Abstract Background C3 glomerulonephritis (C3GN) is a rare form of glomerulopathy that is
characterized by predominant C3 deposits. Eculizumab, a humanized monoclonal C5 …

Results The subjects included three patients with dense deposit disease (including one
patient with recurrent dense deposit disease in allograft) and three patients with C3 …